APA (7th ed.) Citation

M, M., F, L., X, Y., J, Y., Y, D., & J, T. (2026). PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway. General physiology and biophysics, 45(2), 153. https://doi.org/10.4149/gpb_2025043

Chicago Style (17th ed.) Citation

M, Ma, Liu F, Yin X, Yue J, Duan Y, and Tang J. "PCSK9 Inhibitor Evolocumab Alleviates Atherosclerosis Progression by Suppressing Endothelial Cell Injury via the ROS/MAPK Pathway." General Physiology and Biophysics 45, no. 2 (2026): 153. https://doi.org/10.4149/gpb_2025043.

MLA (9th ed.) Citation

M, Ma, et al. "PCSK9 Inhibitor Evolocumab Alleviates Atherosclerosis Progression by Suppressing Endothelial Cell Injury via the ROS/MAPK Pathway." General Physiology and Biophysics, vol. 45, no. 2, 2026, p. 153, https://doi.org/10.4149/gpb_2025043.